Memphasys Completes Felix System Clinical Trial, Shares Rise Past 14%

MT Newswires Live

Feb 11

Memphasys (ASX:MEM) completed a clinical trial of its advanced sperm selection technology, Felix System, for assisted reproductive technology procedures, according to a Tuesday Australian bourse filing.

It achieved the last patient visit in the trial, with all required patient visits, including pregnancy outcomes completed, the filing said.

Data lock is anticipated in around two weeks, following a final data clean-up, management, and source verification phase.

It will use the trial data as part of its ongoing CE Mark submission to advanced commercialization activities in Europe. Regulatory approvals in Australia and India are expected to follow soon after.

The firm's shares rose past 14% on market close on Tuesday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2510878158"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2510878158\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2510878158?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-11 15:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2510878158","market":"sh","top_or_hot":-1,"title":"Memphasys Completes Felix System Clinical Trial, Shares Rise Past 14%","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/MEM.AU\">Memphasys</a> (ASX:MEM) completed a clinical trial of its advanced sperm selection technology, Felix System, for assisted reproductive technology procedures, according to a Tuesday Australian bourse filing.</p><p>It achieved the last patient visit in the trial, with all required patient visits, including pregnancy outcomes completed, the filing said.</p><p>Data lock is anticipated in around two weeks, following a final data clean-up, management, and source verification phase.</p><p>It will use the trial data as part of its ongoing CE Mark submission to advanced commercialization activities in Europe. Regulatory approvals in Australia and India are expected to follow soon after.</p><p>The firm's shares rose past 14% on market close on Tuesday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Memphasys Completes Felix System Clinical Trial, Shares Rise Past 14%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMemphasys Completes Felix System Clinical Trial, Shares Rise Past 14%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-02-11 15:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/MEM.AU\">Memphasys</a> (ASX:MEM) completed a clinical trial of its advanced sperm selection technology, Felix System, for assisted reproductive technology procedures, according to a Tuesday Australian bourse filing.</p><p>It achieved the last patient visit in the trial, with all required patient visits, including pregnancy outcomes completed, the filing said.</p><p>Data lock is anticipated in around two weeks, following a final data clean-up, management, and source verification phase.</p><p>It will use the trial data as part of its ongoing CE Mark submission to advanced commercialization activities in Europe. Regulatory approvals in Australia and India are expected to follow soon after.</p><p>The firm's shares rose past 14% on market close on Tuesday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"XJO.AU","symbol_name":"标普/澳交所 200指数","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2510878158","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2510878158","pubTimestamp":1739257236,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Memphasys  completed a clinical trial of its advanced sperm selection technology, Felix System, for assisted reproductive technology procedures, according to a Tuesday Australian bourse filing.It achieved the last patient visit in the trial, with all required patient visits, including pregnancy outcomes completed, the filing said.Data lock is anticipated in around two weeks, following a final data clean-up, management, and source verification phase.It will use the trial data as part of its ongoing CE Mark submission to advanced commercialization activities in Europe. Regulatory approvals in Australia and India are expected to follow soon after.The firm's shares rose past 14% on market close on Tuesday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"XJO.AU":"标普/澳交所 200指数","MEM":"Matthews Emerging Markets Equity Active ETF","BK7048":"生命科学工具和服务","XKO.AU":"标普/澳交所 300指数","XAO.AU":"标普/澳交所 普通股指数","MEM.AU":"Memphasys"},"translate_title":"Memphasys完成Felix系统临床试验，股价上涨逾14%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XJO.AU":0.81,"MEM":1,"MEM.AU":0.9,"XKO.AU":0.81,"XAO.AU":0.81},"content_text":"Memphasys (ASX:MEM) completed a clinical trial of its advanced sperm selection technology, Felix System, for assisted reproductive technology procedures, according to a Tuesday Australian bourse filing.It achieved the last patient visit in the trial, with all required patient visits, including pregnancy outcomes completed, the filing said.Data lock is anticipated in around two weeks, following a final data clean-up, management, and source verification phase.It will use the trial data as part of its ongoing CE Mark submission to advanced commercialization activities in Europe. Regulatory approvals in Australia and India are expected to follow soon after.The firm's shares rose past 14% on market close on Tuesday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}